Flare

Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023

Retrieved on: 
Thursday, May 4, 2023
Flare, University, Gastroenterology, McCormick Place, Research, Gastroparesis, Abdominal pain, Associate, Stomach, Vomiting, DDW, MD, Patient, Machine learning, DGP, Nausea, Metoclopramide, FDA, Pharmaceutical industry, Medicine

SOLANA BEACH, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the abstract entitled “Reducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide” will be presented at Digestive Disease Week (DDW) 2023 taking place from May 6-9, 2023 at the McCormick Place, Chicago.

Key Points: 
  • These real-world data were selected for presentation alongside a total of only six (6) meritorious clinical abstracts from more than 3,500 that were submitted.
  • In addition, Evoke Pharma will showcase their GIMOTI nasal spray and supporting educational materials at DDW booth #3334.
  • AGA Distinguished Plenary Presentation Title: “Reducing Real-World Healthcare Resource Utilization for Patients with Diabetic Gastroparesis (DGP)
    2.
  • Poster Presentation Title: “Use of Machine Learning to Identify Gastroparesis Patient Appropriate for Nasal Spray Metoclopramide” (Poster Number:

SAA's 5th Annual Global Spondyloarthritis Summit Empowers Patient Community with Access to Health Experts & Information

Retrieved on: 
Thursday, May 4, 2023
Flare, Diet, Genetics, Sleep, Cardiovascular disease, SAA, PDT, Spondylitis, Novartis, Patient, AbbVie, Cannabis, Disease, Nursing, Spondyloarthropathy

ENCINO, Calif., May 3, 2023 /PRNewswire-PRWeb/ -- As an integral component of its mission and ongoing commitment to providing programs to educate and empower the spondyloarthritis (SpA) community, the Spondylitis Association of America (SAA) will host its 5th Annual Global Spondyloarthritis Summit, May 5- 6, 2023. This year's educational program provides attendees access to 12 presentations covering advanced and introductory topics such as treatment options, diet and nutrition, genetics, sleep and spondyloarthritis, gender differences, surgery recommendations, cannabis, cardiovascular disease, flares, and more. Free access to Summit presentations begins at 9 am PDT on Friday, May 5, 2023.

Key Points: 
  • As an integral component of its mission and ongoing commitment to providing programs to educate and empower the spondyloarthritis community, SAA will host its 5th Annual Global Spondyloarthritis Summit, May 5- 6, 2023.
  • ENCINO, Calif., May 3, 2023 /PRNewswire-PRWeb/ -- As an integral component of its mission and ongoing commitment to providing programs to educate and empower the spondyloarthritis (SpA) community, the Spondylitis Association of America (SAA) will host its 5th Annual Global Spondyloarthritis Summit , May 5- 6, 2023.
  • Free access to Summit presentations begins at 9 am PDT on Friday, May 5, 2023.
  • "The Global Spondyloarthritis Summit is just one example of our ongoing commitment to empowering the SpA community, and we are proud to be able to offer access to this content – all at no charge," Shafer added.

Vespene Energy and Viridi Energy Launch Pilot Using Landfill Methane Emissions to Power Onsite Data Processing

Retrieved on: 
Tuesday, May 2, 2023
Electricity, Gasoline, EPA, Methane, StarCraft, Flare, Partnership, RNG, Research, NASA, Carbon, Landfill, Natural gas, Viridi

BERKELEY, Calif., May 2, 2023 /PRNewswire/ -- Vespene Energy ("Vespene"), a biogas renewable energy developer, and Viridi Energy ("Viridi"), a full-service renewable natural gas (RNG) platform, today announced the launch of their first joint pilot site with a municipal landfill in Marathon County, Wisconsin. Vespene and Viridi are using highly-efficient energy generation equipment to convert the naturally occurring landfill byproduct of methane gas into electricity that powers a variety of on-site uses, including data processing.

Key Points: 
  • Vespene and Viridi are using highly-efficient energy generation equipment to convert the naturally occurring landfill byproduct of methane gas into electricity that powers a variety of on-site uses, including data processing.
  • The pilot project will reduce greenhouse gas emissions, while generating revenue to subsidize Viridi's investment in building a state-of-the-art RNG facility at the landfill.
  • "Unlike traditional offtakers of landfill gas, Vespene's technology solution brings revenue-generating, energy-efficient data centers onsite and is immediately deployable and highly scalable," said Vespene Energy co-founder and CEO Adam Wright.
  • "This enables municipal landfill operators to monetize an otherwise stranded asset while reducing harmful greenhouse gas emissions quickly and economically."

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

Retrieved on: 
Tuesday, May 2, 2023
Flare, Argyreia nervosa, Therapy, Week, Food, Fever, Pharmacokinetics, Șaeș, JAMA Dermatology, Pain, Congress, European Academy of Allergy and Clinical Immunology, Patient, SAN, Nausea, GPP, CGI, FDA, Recurrence, Safety, GEMINI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Skin, Immunoglobulin G, Pharmaceutical industry, Dermatology

A potentially debilitating and life-threatening systemic inflammatory skin disease, GPP affects an estimated 15,000 to 37,000 individuals in the U.S.

Key Points: 
  • A potentially debilitating and life-threatening systemic inflammatory skin disease, GPP affects an estimated 15,000 to 37,000 individuals in the U.S.
  • Initial top-line Phase 2 study results were presented at European Academy of Dermatology and Venerology (EADV) Congress in October 2021.
  • The U.S. Food and Drug Administration granted Orphan Drug Designation to imsidolimab for the treatment of GPP in July 2020.
  • AnaptysBio announced in August 2022 that it intends to complete execution of the GEMINI Phase 3 GPP program and out license imsidolimab prior to potential FDA approval.

SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares

Retrieved on: 
Tuesday, May 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Flare, Executive officer, Safety, Dermatology, Breakthrough therapy, BTD, Multimedia, Boehringer Ingelheim, Congress, National Medical Products Administration, CDE, GPP, FDA, Center for Drug Evaluation and Research, Regulation of tobacco by the U.S. Food and Drug Administration, NMPA, Food, Pharmaceutical industry

Boehringer Ingelheim announced today that spesolimab (marketed as SPEVIGO®) received Breakthrough Therapy Designation (BTD) as an investigational treatment for the prevention of flares in adolescents and adults with generalized pustular psoriasis (GPP) from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • Boehringer Ingelheim announced today that spesolimab (marketed as SPEVIGO®) received Breakthrough Therapy Designation (BTD) as an investigational treatment for the prevention of flares in adolescents and adults with generalized pustular psoriasis (GPP) from the U.S. Food and Drug Administration (FDA).
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230502005731/en/
    “GPP flares may appear suddenly, intensify quickly, and can be life-threatening if left untreated, leaving those affected feeling anxious and uncertain about their future” said Carinne Brouillon, Member of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim.
  • Data from the trial will be presented at the 25th World Congress of Dermatology 2023 in early July.

Wrangler® Signs Country Music Star Lainey Wilson

Retrieved on: 
Tuesday, May 2, 2023
Textiles, Entertainment, Marketing, Advertising, Communications, Manufacturing, Celebrity, Fashion, Music, Retail, Collection, Female, CMA, Face, Lainey Wilson, Woman, Human, Multimedia, Bell Bottom Country, Wilson, PRCA, Flare, Academy of Country Music Awards, Social media, Country, Boilermaker, Wrangler

Global denim brand Wrangler® today announced a multi-year collaboration with reigning CMA Female Vocalist of the Year, most nominated female at the 2023 ACM Awards and Yellowstone actress Lainey Wilson.

Key Points: 
  • Global denim brand Wrangler® today announced a multi-year collaboration with reigning CMA Female Vocalist of the Year, most nominated female at the 2023 ACM Awards and Yellowstone actress Lainey Wilson.
  • View the full release here: https://www.businesswire.com/news/home/20230502005238/en/
    Global denim brand Wrangler® today announced a multi-year collaboration with reigning CMA Female Vocalist of the Year, most nominated female at the 2023 ACM Awards and Yellowstone actress Lainey Wilson.
  • The brand will continue to team up with Wilson in 2024 with Wilson as the face of Wrangler women’s next spring and a Wrangler x Lainey Wilson Capsule Collection expected in the fall of 2024.
  • To see Wilson’s favorite Wrangler picks and more about the Wilson and Wrangler duo follow @wrangler and @laineywilsonmusic .

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

Retrieved on: 
Tuesday, May 2, 2023
Infection, Flare, Heart failure, Hospital, TB, Kidney, Medicine, History, Marketing, Sepsis, Boehringer Ingelheim, Breakthrough therapy, Patient, Tuberculosis, Risk, Immune system, Torosyan v. Boehringer Ingelheim Pharmaceuticals, Inc., GPP, FDA, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mental health, Food, Safety, Birth control, Pharmaceutical industry, Dermatology

GPP is a rare and potentially life-threatening chronic neutrophilic skin disease characterized by flares of widespread eruptions of painful, sterile pustules across the body.

Key Points: 
  • GPP is a rare and potentially life-threatening chronic neutrophilic skin disease characterized by flares of widespread eruptions of painful, sterile pustules across the body.
  • Flares greatly affect a person's quality of life and can lead to hospitalization with serious complications, including heart failure, renal failure, sepsis, and death.
  • "The FDA's action reinforces the potential of spesolimab and represents a critical step in bringing this treatment to patients who need it most.
  • Spesolimab is marketed as SPEVIGO (spesolimab-sbzo) injection, for intravenous use by Boehringer Ingelheim
    Pharmaceuticals, Inc. (BIPI) and is indicated for the treatment of GPP flares in adults.

Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023

Retrieved on: 
Thursday, April 27, 2023
Flare, University of Hong Kong, Therapy, Virology, Cohort, Department of Medicine – University of Pamplona, NA, Clinical trial, Viral, CFBV, RNA, Antibody, AASLD, Hepatology, Patient, Division, University, Immune system, ALT, RNA interference, HBV, Vaccine, Pharmaceutical industry, HBeAg, HBsAg, Gastroenterology

WARMINSTER, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that clinical data for AB-729, an RNAi therapeutic, and preclinical data for AB-161, a next-generation oral HBV specific RNA destabilizer, were presented as late-breaker oral presentations at the Global Hepatitis Summit 2023 in Paris.

Key Points: 
  • The data show that AB-161 provides robust anti-HBV activity including suppression of HBV RNA and HBsAg production in vitro and in vivo.
  • Data from the mechanism of action studies show that AB-161 promotes viral transcript degradation and reduces viral proteins and viral replication.
  • Preclinical pharmacokinetic data and repeat dose toxicology studies show enhanced liver concentrations and lack of peripheral neuropathy.
  • We have recently initiated a Phase 1 clinical trial in healthy subjects and look forward to sharing the initial data in the second half of this year.”

Top Neurosurgeon, Dr. Albert Wong, of Los Angeles' DOCS Health will be Presenting at the Upcoming "5th Annual Global Spondyloarthritis Virtual Summit" in May

Retrieved on: 
Wednesday, April 19, 2023
Education, Flare, Gastrointestinal tract, Arthritis, Ligament, Neoplasm, Diet (nutrition), University, Health, Cardiovascular disease, PDT, Spine, Rheumatology, Inflammation, Suite, Stanford University School of Medicine, MISS, LOS, Northwestern University, Tendon, Disease, Dentistry, Spondyloarthropathy

LOS ANGELES, April 19, 2023 /PRNewswire-PRWeb/ -- As the premier virtual health event for the spondyloarthritis community, the "5th Annual Global Spondyloarthritis Summit" features renowned rheumatologists and other health experts who will provide the most up-to-date findings and comprehensive information on essential topics that relate to the disease. Under the theme "Moving Together Towards Better Health Outcomes" this year's free virtual program features 12 experts, including Dr. Albert Wong, from the international community who will be discussing the following subjects, "Flares and Possible Triggers," "Diet & Nutrition," "Surgery & Joint Replacement Recommendations," "Cardiovascular Disease," and more. Specifically, Dr. Wong will lead a discussion on the topic "When is Joint Replacement and Spine Surgery Recommended?" on May 5, 2023, at 2:00 PDT. Spondyloarthritis is the term for a group of inflammatory diseases that cause joint inflammation, or arthritis. Spondyloarthritis can be classified as either axial or peripheral. The axial form affects mostly the pelvic joints and spine. The peripheral form affects the limbs. The condition may also cause inflammation in the eyes, gastrointestinal tract and areas where ligaments and tendons attach to bones.

Key Points: 
  • Specifically, Dr. Wong will lead a discussion on the topic "When is Joint Replacement and Spine Surgery Recommended?"
  • Spondyloarthritis is the term for a group of inflammatory diseases that cause joint inflammation, or arthritis.
  • DOCS Health is located at 8436 W. 3rd St, Suite 800, in Los Angeles, CA.
  • For more information or to schedule a consultation with one of DOCS Health specialists, please call (424) 800-3627 or visit http://www.docshealth.com .

Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare's Precision Oncology Pipeline

Retrieved on: 
Thursday, April 13, 2023
Partnership, Drug development, Biotechnology, Clinical trial, Cancer, Intelligence, Biomarker, Sequence, Patient, Machine learning, Medicine, Biology, Growth, Therapy, Factorization of polynomials, Disease, Pharmaceutical industry, Medical imaging, Flare

Under the terms of the agreement, Flare will leverage Caris' industry-leading next generation sequencing technology for the molecular testing of patients treated with Flare's assets.

Key Points: 
  • Under the terms of the agreement, Flare will leverage Caris' industry-leading next generation sequencing technology for the molecular testing of patients treated with Flare's assets.
  • In addition, Flare will receive access to Caris' data insights and analytics capabilities to accelerate oncology drug discovery, identify novel biomarkers and optimize clinical positioning strategies for their pipeline.
  • Flare will also leverage Caris' biomarker-driven patient selection for clinical trials, allowing Caris the first option to develop a companion diagnostic for any drug candidate developed as part of the collaboration.
  • "The data accessibility and continuum across real world and clinical trial populations will provide Flare the necessary insights for successful molecule discovery and development."